Parallel Advisors’s Psyence Biomedical PBM Stock Holding History

Parallel Advisors’s Portfolio PBM Stock Details PBM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$575K	Hold	151,250	–	–	0.01%	729
2026 Q1	$575K	Buy	151,250 +127,050	+525%	+$418K	0.01%	670
2025 Q4	$687K	Hold	24,200	–	–	0.01%	575
2025 Q3	$687K	Sell	24,200 -19,800	-45%	-$544K	0.01%	554
2025 Q2	$462K	Buy	+44,000	New	+$1.22M	0.01%	664

Parallel Advisors's PBM Position: Q2 2026 in Review

Parallel Advisors held its Psyence Biomedical (PBM) position steady in Q2 2026 at 151,250 shares worth $575K. The position accounts for 0.01% of the portfolio, ranked #729.

Parallel Advisors first reported a position in PBM in Q2 2025 and has held it in 5 quarters since. The position peaked at $687K in Q4 2025. 1 fund tracked by Wall St. Rank holds PBM as of Q2 2026.

Parallel Advisors held 151,250 shares of Psyence Biomedical worth $575K as of Q2 2026.
Parallel Advisors left its Psyence Biomedical share count unchanged in Q2 2026.
Psyence Biomedical made up 0.01% of Parallel Advisors's portfolio in Q2 2026, its #729 holding.
Parallel Advisors first reported a position in Psyence Biomedical in Q2 2025 and has held it in 5 quarters since.
Parallel Advisors's Psyence Biomedical position peaked at $687K in Q4 2025.
1 fund tracked by Wall St. Rank held Psyence Biomedical as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.